Danaher (DHR) Q2 FY26 earnings call

Danaher reported a solid second quarter with better-than-expected revenue, earnings, and cash flow, driven by accelerating core growth across its portfolio and strong commercial execution. Despite customer project timing impacting bioprocessing revenue, underlying order trends remain robust, and the company raised its full-year adjusted EPS guidance following the early close of the Masimo acquisition. Management is encouraged by stabilizing end markets and expects continued momentum into the second half of the year.